摘要
The aim of this study was to assess the cost-effectiveness of pembrolizumab versus chemotherapy for metastatic colorectal cancer (mCRC) patients with mismatch-repair deficiency or microsatellite instability-high (dMMR/MSI-H) in China. A partitioned survival model was constructed to determine the costs and effects of pembrolizumab and chemotherapy based on KEYNOTE-177 trial outcomes data. Health outcomes were measured in quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs). The Chinese health service system perspective was considered. A willing-to-pay threshold was set at 35,832 USD/QALY, which was three times the gross domestic product (GDP) per capita of China in 2021. We examined the robustness of the model in the one-way and probabilistic sensitivity analysis. Pembrolizumab was associated with better health outcomes than chemotherapy (5.30 vs 3.37 QALYs). Compared with chemotherapy, the pembrolizumab strategy yielded an incremental cost of $16 032.57, which resulted in an ICER of $8285 per QALY. The cost of pembrolizumab and chemotherapy had the largest impact on the ICER. The parameters with less influence on the ICER were utility values of the Post-PFS state. Compared to chemotherapy, pembrolizumab had the economic advantage as the first-line treatment of mCRC patients with dMMR/MSI-H in China.
学科与关键词
- Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158Wu, X.; Mao, Y.; Xu, N.; Bai, Y.; Wang, D.; Chen, X.; Yin, X.; Deng, Y.; Yang, J.; Zhang, J.; Tang, J.; Huang, Y.; Li, J.; Xu, M.; Li, N.; Mao, Y.; Gozman, A.; Xu, J.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
- Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158Mao, Y.; Wu, X.; Xu, N.; Bai, Y.; Wang, D.; Chen, X.; Yin, X.; Deng, Y.; Yang, J.; Zhang, J.; Tang, J.; Huang, Y.; Li, J.; Xu, M.; Li, N.; Mao, Y.; Gozman, A.; Xu, J.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
- A cost-effectiveness analysis of first-line toripalimab plus chemotherapy in advanced nonsquamous non-small cell lung cancer in ChinaZheng, Zhiwei; Zhu, Gaofeng; Cao, Xueqiong; Cai, Hongfu*; Zhu, Huide*Expert Review of Clinical Pharmacology, 2023, 16(3): 267-273.被引 2
